Fig. 6
From: Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models
Effects of combined BRAF/MEK inhibition in isogenic cell lines with different KRAS mutational background. Growth inhibitory interactions between trametinib and dabrafenib were assessed in CRC cancer cells HCT116 and clones HKE-3 (KRASG13D/G13D) and HK2–6 (KRASwt/wt) and in NSCLC cell line H1299 K4 (KRAS-wt) and clones C2 (KRASG12C) D2 (KRASG12D) and V9 (G12V). Viability was then assessed after 72 h by Crystal violet assay and pharmacologic interactions were evaluated using the Calcusyn software. CI were plotted against the fraction affected